Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
- Revenue in USD (TTM)468.00k
- Net income in USD-82.47m
- Incorporated2015
- Employees90.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| iTeos Therapeutics Inc | 35.00m | -108.14m | 423.29m | 157.00 | -- | 0.6376 | -- | 12.09 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Instil Bio Inc | 0.00 | -119.58m | 429.91m | 49.00 | -- | 2.20 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
| Grail Inc | 109.74m | -2.88bn | 431.89m | 1.37k | -- | 0.1603 | -- | 3.94 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Larimar Therapeutics Inc | 0.00 | -58.34m | 437.08m | 42.00 | -- | 2.07 | -- | -- | -1.11 | -1.11 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -33.44 | -42.22 | -36.41 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Taysha Gene Therapies Inc | 12.87m | -114.34m | 440.63m | 52.00 | -- | 3.98 | -- | 34.23 | -0.8987 | -0.8987 | 0.0643 | 0.5406 | 0.0913 | -- | -- | 247,557.70 | -81.11 | -- | -116.01 | -- | -- | -- | -888.18 | -- | -- | -- | 0.2598 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 441.85m | 181.00 | -- | 1.11 | -- | 35.87 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| C4 Therapeutics Inc | 29.38m | -107.87m | 442.37m | 145.00 | -- | 1.78 | -- | 15.06 | -1.90 | -1.90 | 0.4944 | 3.59 | 0.0777 | -- | 26.77 | 202,606.90 | -28.53 | -25.91 | -33.00 | -29.45 | -- | -- | -367.17 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Absci Corp | 3.25m | -92.26m | 451.95m | 155.00 | -- | 2.04 | -- | 139.06 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| PureTech Health PLC (ADR) | 468.00k | -82.47m | 454.84m | 90.00 | -- | -- | -- | 971.88 | -3.01 | -3.01 | 0.0171 | -- | 0.0007 | -- | 0.2252 | 5,200.00 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| ACELYRIN Inc | 0.00 | -299.80m | 459.12m | 130.00 | -- | 0.8061 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| SAGE Therapeutics Inc | 97.24m | -445.67m | 463.37m | 487.00 | -- | 0.7359 | -- | 4.77 | -7.41 | -7.41 | 1.62 | 10.31 | 0.1093 | -- | 6.75 | 199,679.70 | -50.09 | -21.88 | -55.24 | -23.30 | 95.47 | 99.63 | -458.30 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Verve Therapeutics Inc | 20.65m | -192.65m | 466.28m | 255.00 | -- | 0.8531 | -- | 22.58 | -2.59 | -2.59 | 0.275 | 6.46 | 0.032 | -- | 8.05 | 80,972.55 | -29.87 | -- | -31.67 | -- | -- | -- | -933.03 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -41.53m | 466.38m | 40.00 | -- | 3.59 | -- | -- | -0.5012 | -0.5012 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -27.75 | -40.04 | -30.03 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -80.69m | 473.74m | 88.00 | -- | 2.47 | -- | -- | -1.79 | -1.79 | 0.00 | 3.86 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Contineum Therapeutics Inc | -100.00bn | -100.00bn | 475.62m | 31.00 | -- | 2.19 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Prime Medicine Inc | 591.00k | -217.44m | 477.72m | 234.00 | -- | 2.43 | -- | 808.33 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to PureTech Health PLC's reporting currency: US Dollar USD
1.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Birch Hill Investment Advisors LLCas of 30 Jun 2024 | 302.00k | 1.26% |
| Pentwater Capital Management LPas of 30 Jun 2024 | 16.19k | 0.07% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.73k | 0.01% |
| Adar1 Capital Management LLCas of 30 Jun 2024 | 700.00 | 0.00% |
| UBS Securities LLCas of 30 Jun 2024 | 331.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 100.00 | 0.00% |
| Tower Research Capital LLCas of 30 Jun 2024 | 73.00 | 0.00% |
| UBS Financial Services, Inc.as of 30 Jun 2024 | 20.00 | 0.00% |
| AWM Investment Co., Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
